Advertisement

Prophylactic sivelestat for esophagectomy and in-hospital mortality: a propensity score-matched analysis of claims database

  • Chikashi Takeda
  • Masato Takeuchi
  • Yohei Kawasaki
  • Hiroshi Yonekura
  • Isao Nahara
  • Aki Kuwauchi
  • Satomi Yoshida
  • Shiro Tanaka
  • Koji KawakamiEmail author
Original Article

Abstract

Purpose

Transthoracic esophagectomy is an invasive surgery, and the excessive surgical stress produces inflammatory cytokines, which provoke acute respiratory distress syndrome (ARDS). Sivelestat sodium hydrate—a selective neutrophil elastase inhibitor—is used to treat or prevent ARDS in patients undergoing esophagectomy, although clear evidence is lacking. We investigated the benefits and risk of prophylactic sivelestat.

Methods

This retrospective study used an administrative claims database in Japan. Adult patients who underwent transthoracic esophagectomy from 2010 to 2016 were identified and divided into a prophylactic sivelestat use group and a non-prophylactic use group that included both non-users and therapeutic users. The primary outcome was all-cause in-hospital mortality, and a secondary outcome included the proportion of ARDS. We used 1:1 propensity score matching. For sensitivity analyses, we conducted a 1:2 propensity score matching analysis and several analyses with various patient inclusion criteria.

Results

Of the 3391 patients with esophagectomy, 621 received prophylactic sivelestat. On unadjusted analysis, the sivelestat group had a higher proportion of in-hospital mortality (5.3% vs. 2.9%) compared with the control group. We created a matched cohort of 615 pairs, whose baseline characteristics were well balanced. On adjusted analysis using propensity score matching, prophylactic sivelestat administration was not associated with decreased in-hospital mortality [adjusted odds ratio (aOR) 1.65; 95% confidence interval (CI) 0.95–2.88], ARDS rate (aOR 1.25; 95% CI 0.49–3.17). The findings were also consistent with other sensitivity analyses.

Conclusion

Because mortality and postoperative complications were similar, our findings do not support prophylactic sivelestat administration for patients undergoing esophagectomy.

Keywords

Esophagectomy Sivelestat Mortality Propensity score Administrative claims 

Notes

Acknowledgements

We acknowledge Professor Kazuhiko Fukuda, M.D., Ph.D. (affiliated with Department of Anesthesia, Graduate School of Medicine, Kyoto University, Kyoto, Japan) for his valuable comments on the study. We also thank Mr. Masaki Nakamura and staff at Medical Data Vision, Co, Ltd. (Tokyo, Japan) for data preparation assistance. We also thank Editage (http://www.editage.jp) for English language editing.

Supplementary material

540_2018_2602_MOESM1_ESM.docx (22 kb)
Supplementary material 1 (DOCX 21 KB)

References

  1. 1.
    Haga Y, Beppu T, Doi K, Nozawa F, Mugita N, Ikei S, Ogawa M. Systemic inflammatory response syndrome and organ dysfunction following gastrointestinal surgery. Crit Care Med. 1997;25:1994–2000.CrossRefGoogle Scholar
  2. 2.
    Avendano CE, Flume PA, Silvestri GA, King LB, Reed CE. Pulmonary complications after esophagectomy. Ann Thorac Surg. 2002;73:922–6.CrossRefGoogle Scholar
  3. 3.
    Bailey SH, Bull DA, Harpole DH, Rentz JJ, Neumayer LA, Pappas TN, Daley J, Henderson WG, Krasnicka B, Khuri SF. Outcomes after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg. 2003;75:217–22.CrossRefGoogle Scholar
  4. 4.
    Bhatia M, Moochhala S. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol. 2004;202:145–56.CrossRefGoogle Scholar
  5. 5.
    Morita M, Yoshida R, Ikeda K, Egashira A, Oki E, Sadanaga N, Kakeji Y, Ichiki Y, Sugio K, Yasumoto K, Maehara Y. Acute lung injury following an esophagectomy for esophageal cancer, with special reference to the clinical factors and cytokine levels of peripheral blood and pleural drainage fluid. Dis Esophagus. 2008;21:30–6.CrossRefGoogle Scholar
  6. 6.
    Tamakuma S, Ogawa M, Aikawa N, Kubota T, Hirasawa H, Ishizaka A, Taenaka N, Hamada C, Matsuoka S, Abiru T. Relationship between neutrophil elastase and acute lung injury in humans. Pulmon Pharmacol Ther. 2004;17:271–9.CrossRefGoogle Scholar
  7. 7.
    Aikawa N, Ishizaka A, Hirasawa H, Shimazaki S, Yamamoto Y, Sugimoto H, Shinozaki M, Taenaka N, Endo S, Ikeda T, Kawasaki Y. Reevaluation of the efficacy and safety of the neutrophil elastase inhibitor, Sivelestat, for the treatment of acute lung injury associated with systemic inflammatory response syndrome; a phase IV study. Pulmon Pharmacol Ther. 2011;24:549–54.CrossRefGoogle Scholar
  8. 8.
    Hayakawa M, Katabami K, Wada T, Sugano M, Hoshino H, Sawamura A, Gando S. Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome and disseminated intravascular coagulation patients. Shock. 2010;33:14–8.CrossRefGoogle Scholar
  9. 9.
    Zeiher BG, Artigas A, Vincent J-L, Dmitrienko A, Jackson K, Thompson BT, Bernard G. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med. 2004;32:1695–702.CrossRefGoogle Scholar
  10. 10.
    Iwahashi M, Nakamori M, Nakamura M, Ojima T, Naka T, Yamaue H. Optimal period for the prophylactic administration of neutrophil elastase inhibitor for patients with esophageal cancer undergoing esophagectomy. World J Surg. 2011;35:1573–9.CrossRefGoogle Scholar
  11. 11.
    Kawahara Y, Ninomiya I, Fujimura T, Funaki H, Nakagawara H, Takamura H, Oyama K, Tajima H, Fushida S, Inaba H, Kayahara M. Prospective randomized controlled study on the effects of perioperative administration of a neutrophil elastase inhibitor to patients undergoing video-assisted thoracoscopic surgery for thoracic esophageal cancer. Dis Esophagus. 2010;23:329–39.CrossRefGoogle Scholar
  12. 12.
    Makino H, Kunisaki C, Kosaka T, Akiyama H, Morita S, Endo I. Perioperative use of a neutrophil elastase inhibitor in video-assisted thoracoscopic oesophagectomy for cancer. Br J Surg. 2011;98:975–82.CrossRefGoogle Scholar
  13. 13.
    Nagai Y, Watanabe M, Baba Y, Iwatsuki M, Hirashima K, Karashima R, Kurashige J, Kinoshita K, Baba H. Preventive effect of sivelestat on postoperative respiratory disorders after thoracic esophagectomy. Surg Today. 2013;43:361–6.CrossRefGoogle Scholar
  14. 14.
    Nishiyama J, Matsuda M, Ando S, Hirasawa M, Suzuki T, Makuuchi H. The effects of the early administration of sivelestat sodium, a selective neutrophil elastase inhibitor, on the postoperative course after radical surgery for esophageal cancer. Surg Today. 2012;42:659–65.CrossRefGoogle Scholar
  15. 15.
    Wang ZQ, Chen LQ, Yuan Y, Wang WP, Niu ZX, Yang YS, Cai J. Effects of neutrophil elastase inhibitor in patients undergoing esophagectomy: a systematic review and meta-analysis. World J Gastroenterol. 2015;21:3720–30.CrossRefGoogle Scholar
  16. 16.
    Ishii M. DRG/PPS and DPC/PDPS as Prospective Payment Systems. Jpn Med Assoc J. 2012;55:279–91.Google Scholar
  17. 17.
    Tanaka S, Seto K, Kawakami K. Pharmacoepidemiology in Japan: medical databases and research achievements. J Pharmaceut Health Care Sci. 2015;1:16.CrossRefGoogle Scholar
  18. 18.
    Fuji T, Akagi M, Abe Y, Oda E, Matsubayashi D, Ota K, Kobayashi M, Matsushita Y, Kaburagi J, Ibusuki K, Takita A, Iwashita M, Yamaguchi T. Incidence of venous thromboembolism and bleeding events in patients with lower extremity orthopedic surgery: a retrospective analysis of a Japanese healthcare database. J Orthopaed Surg Res. 2017;12:55.CrossRefGoogle Scholar
  19. 19.
    Kanazawa Y, Takeuchi M, Tateya I, Omori K, Kawakami K. Clinical epidemiology of tracheal invasion from thyroid cancer in Japanese population: functional outcomes and effect of aging. Cancer Epidemiol. 2017;50:107–12.CrossRefGoogle Scholar
  20. 20.
    Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol. 2017;27:476–82.CrossRefGoogle Scholar
  21. 21.
    Austin PC. Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement. J Thorac Cardiovasc Surg. 2007;134:1128–35.CrossRefGoogle Scholar
  22. 22.
    Law S, Wong KH, Kwok KF, Chu KM, Wong J. Predictive factors for postoperative pulmonary complications and mortality after esophagectomy for cancer. Ann Surg. 2004;240:791–800.CrossRefGoogle Scholar
  23. 23.
    Hashimoto S, Sanui M, Egi M, Ohshimo S, Shiotsuka J, Seo R, Tanaka R, Tanaka Y, Norisue Y, Hayashi Y, Nango E. The clinical practice guideline for the management of ARDS in Japan. J Intensive Care. 2017;5:50.CrossRefGoogle Scholar
  24. 24.
    Tagami T, Matsui H, Ishinokami S, Oyanagi M, Kitahashi A, Fukuda R, Unemoto K, Fushimi K, Yasunaga H. Amiodarone or nifekalant upon hospital arrival for refractory ventricular fibrillation after out-of-hospital cardiac arrest. Resuscitation. 2016;109:127–32.CrossRefGoogle Scholar
  25. 25.
    Tagami T, Matsui H, Fushimi K, Yasunaga H. Supplemental dose of antithrombin use in disseminated intravascular coagulation patients after abdominal sepsis. Thromb Haemost. 2015;114:537–45.CrossRefGoogle Scholar
  26. 26.
    Takeuchi H, Miyata H, Gotoh M, Kitagawa Y, Baba H, Kimura W, Tomita N, Nakagoe T, Shimada M, Sugihara K, Mori M. A risk model for esophagectomy using data of 5354 patients included in a Japanese nationwide web-based database. Ann Surg. 2014;260:259–66.CrossRefGoogle Scholar
  27. 27.
    Malhotra A, Maughan D, Ansell J, Lehman R, Henderson A, Gray M, Stephenson T, Bailey S. Choosing Wisely in the UK: the Academy of Medical Royal Colleges’ initiative to reduce the harms of too much medicine. Br Med J. 2015;350:h2308.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Anesthesiologists 2019

Authors and Affiliations

  • Chikashi Takeda
    • 1
    • 2
  • Masato Takeuchi
    • 1
  • Yohei Kawasaki
    • 1
    • 3
  • Hiroshi Yonekura
    • 1
  • Isao Nahara
    • 1
  • Aki Kuwauchi
    • 1
  • Satomi Yoshida
    • 1
  • Shiro Tanaka
    • 1
    • 4
  • Koji Kawakami
    • 1
    Email author
  1. 1.Department of Pharmacoepidemiology, Graduate School of Medicine and Public HealthKyoto UniversityKyotoJapan
  2. 2.Department of Anesthesia, Graduate School of MedicineKyoto UniversityKyotoJapan
  3. 3.Biostatistics Section, Clinical Research CenterChiba University HospitalChibaJapan
  4. 4.Department of Clinical Biostatistics/Clinical Biostatistics Course, Graduate School of MedicineKyoto UniversityKyotoJapan

Personalised recommendations